Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Taste of Abrocitinib Oral Formulations
NCT04903093Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of abrocitinib in atopic dermatitis (AD) (5 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at 48 hours, Maximum Plasma Concentration at 48 hours and 7 more. Started Jun 2021; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04903093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903093.